Details for New Drug Application (NDA): 010971

✉ Email this page to a colleague

NDA 010971 describes PMB 400, which is a drug marketed by Wyeth Ayerst and is included in one NDA. Additional details are available on the PMB 400 profile page.

The generic ingredient in PMB 400 is estrogens, conjugated; meprobamate. There are three drug master file entries for this compound. Additional details are available on the estrogens, conjugated; meprobamate profile page.

Summary for 010971

Tradename:	PMB 400
Applicant:	Wyeth Ayerst
Ingredient:	estrogens, conjugated; meprobamate
Patents:	0

Profile for product number 003

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	0.45MG;400MG
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	No

Profile for product number 005

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	0.45MG;200MG
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	No

Expired US Patents for NDA 010971

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Ayerst	PMB 200	estrogens, conjugated; meprobamate	TABLET;ORAL	010971-005	Approved Prior to Jan 1, 1982	⤷ Get Started Free	⤷ Get Started Free
Wyeth Ayerst	PMB 400	estrogens, conjugated; meprobamate	TABLET;ORAL	010971-003	Approved Prior to Jan 1, 1982	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.